Evidence map›Paper›PMID 22833495›Full record

ArticleBriefings in bioinformatics2012

Reverse engineering biomolecular systems using -omic data: challenges, progress and opportunities.

Chang F Quo, Chanchala Kaddi, John H Phan, Amin Zollanvari, Mingqing Xu, May D Wang, Gil Alterovitz

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Multiscale models of breast cancer progression.Annals of biomedical engineering · 2012
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chang F QuoGeorgia Institute of Technology, Atlanta, GA 30332, USA.
Chanchala Kaddi
John H Phan
Amin Zollanvari
Mingqing Xu
May D Wang
Gil Alterovitz

Funding

Tissue and Animal UseU54CA119338 · NCI · EMORY UNIVERSITY · PI BAO, GANG · 2005 to 2009
$18.4M
Nanotechnology Linking Biomarkers with Cancer BehaviorR01CA108468 · NCI · EMORY UNIVERSITY · PI NIE, SHUMING · 2004 to 2008
$6.9M
Nanotechnology for Multiplexed and Intraoperative Cancer DetectionRC2CA148265 · NCI · EMORY UNIVERSITY · PI NIE, SHUMING · 2009 to 2010
$2.0M
Automated Integration of Biomedical KnowledgeR01HG004836 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI ALTEROVITZ, GIL · 2009 to 2010
$856k
A Holistic Approach to Information Processing for Biomedical NetworksR00LM009826 · NLM · BOSTON CHILDREN'S HOSPITAL · PI ALTEROVITZ, GIL · 2010 to 2012
$727k
Beyond Association: Predictive Modeling of Nicotine DependanceR21DA025168 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI ALTEROVITZ, GIL · 2008 to 2009
$350k
NCI NIH HHS 1RC2CA148265NCI NIH HHS R01CA108468NCI NIH HHS U54CA119338NHGRI NIH HHS 1R01HG004836-01NIDA NIH HHS 5R21DA025168-02NLM NIH HHS 4R00LM009826-03
6 · The paper itself

Abstract

Recent advances in high-throughput biotechnologies have led to the rapid growing research interest in reverse engineering of biomolecular systems (REBMS). 'Data-driven' approaches, i.e. data mining, can be used to extract patterns from large volumes of biochemical data at molecular-level resolution while 'design-driven' approaches, i.e. systems modeling, can be used to simulate emergent system properties. Consequently, both data- and design-driven approaches applied to -omic data may lead to novel insights in reverse engineering biological systems that could not be expected before using low-throughput platforms. However, there exist several challenges in this fast growing field of reverse engineering biomolecular systems: (i) to integrate heterogeneous biochemical data for data mining, (ii) to combine top-down and bottom-up approaches for systems modeling and (iii) to validate system models experimentally. In addition to reviewing progress made by the community and opportunities encountered in addressing these challenges, we explore the emerging field of synthetic biology, which is an exciting approach to validate and analyze theoretical system models directly through experimental synthesis, i.e. analysis-by-synthesis. The ultimate goal is to address the present and future challenges in reverse engineering biomolecular systems (REBMS) using integrated workflow of data mining, systems modeling and synthetic biology.

Indexed as

Systems BiologyBioengineeringBiotechnologyData Mining

Identifiers

PMID22833495
PMCPMC3404400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.